Examples of 'anidulafungin' in a sentence
Meaning of "anidulafungin"
anidulafungin (noun) - Anidulafungin is a type of antifungal medication used to treat certain fungal infections in healthcare settings. It belongs to the echinocandin class of antifungals
Show more definitions
- An antifungal drug of the echinocandin class.
How to use "anidulafungin" in a sentence
Basic
Advanced
anidulafungin
Hepatic metabolism of anidulafungin has not been observed.
Anidulafungin is not evidently metabolized by the liver.
It is unknown whether anidulafungin is excreted in human milk.
It contains the active substance anidulafungin.
Therefore anidulafungin is not recommended in pregnancy.
No specific tissue distribution studies of anidulafungin have been done in humans.
Anidulafungin is not hepatically metabolised.
It is not known whether anidulafungin is excreted in human breast milk.
Anidulafungin is manufactured via semisynthesis.
Plasma concentrations of anidulafungin in healthy men and women were similar.
Anidulafungin is at least as effective as fluconazole in the treatment of invasive candidiasis.
Animal studies have shown excretion of anidulafungin in breast milk.
Anidulafungin was not genotoxic in mice using the in vivo micronucleus assay.
The active substance is anidulafungin.
Anidulafungin crossed the placental barrier in rats and was detected in foetal plasma.
See also
There are no data regarding the use of anidulafungin in pregnant women.
Anidulafungin concentrations were not increased in subjects with any degree of hepatic insufficiency.
There are no data from the use of anidulafungin in pregnant women.
Anidulafungin is not dialysable and may be administered without regard to the timing of hemodialysis.
This compound is known as anidulafungin.
Hepatic insufficiency Anidulafungin is not hepatically metabolised.
Two safety pharmacology studies revealed hemodynamic changes when anidulafungin was administered to rats.
Anidulafungin is a derivative of an Aspergillus metabolite.
Eraxis contains the medicinal ingredient anidulafungin which is an antifungal agent.
The anidulafungin curve is based upon the curves reported in the package insert for Eraxis.
In vitro and in vivo genotoxicity studies with anidulafungin provided no evidence of genotoxic potential.
Anaphylactic reactions, including shock, were reported with the use of anidulafungin.
Candida isolates with reduced susceptibility to anidulafungin have not been isolated from treated patients.
Anidulafungin concentrations fell below the lower limits of quantitation 6 days post-dose.
The in vitro activity of anidulafungin against Candida species is not uniform.
Long-term studies in animals have not been conducted to evaluate the carcinogenic potential of anidulafungin.
If these reactions occur, anidulafungin should be discontinued and appropriate treatment administered.
Nevertheless, care should be taken when co-administering anidulafungin and anaesthetic agents.
The pharmacokinetics of anidulafungin have been characterised in healthy subjects, special populations and patients.
EUCAST has not determined non-species related breakpoints for anidulafungin.
Drug interaction studies were performed with anidulafungin and other medicinal products likely to be co-administered.
Anidulafungin did not produce any drug-related developmental toxicity in rats at the highest dose tested.
Stability of compound 22 and anidulafungin in various mammalian plasmas and in PBS.
Anidulafungin is a semi-synthetic echinocandin, a lipopeptide synthesised from a fermentation product of Aspergillus nidulans.
Mortality rates in both the anidulafungin and fluconazole arms are presented below in Table 2.
Global success in the MITT population, primary and secondary endpoints Anidulafungin Fluconazole.
In general, anidulafungin concentrations and exposures were dose-proportional for the clinically relevant dose levels.
Similarly, C. parapsilosis isolates intermediate to anidulafungin and micafungin can be regarded intermediate to caspofungin.
Anidulafungin has negligible renal clearance < 1.
Repeat-Dose Toxicity In rats and monkeys, repeat doses of anidulafungin produced hepatotoxic effects.
The efficacy of anidulafungin in adult neutropenic patients defined as absolute neutrophil count ≤ 500 cells / mm.
Pharmacokinetics of compound 22 and anidulafungin in chimpanzee.
Anidulafungin pharmacokinetics were similar among Caucasians, Blacks, Asians, and Hispanics.
The clearance of anidulafungin is about 1 l / h.
One hundred and nineteen patients received ≥ 14 days of anidulafungin.
